This observation has been supported by studies that used CRISPR/Cas9 to knockout the PD-1 receptor in Glypican-3 (GPC3) targeted CAR-T cells in both in vitro and in vivo models of human hepatocellular carcinoma. This evidence concerns the gene GPC3 and hepatocellular carcinoma.